Magnus Medical Highlights New Clinical Data on Groundbreaking SAINT Therapy at 2024 NYC Neuromodulation Conference
New Research shows promising, sustained results for personalized treatment of treatment-resistant depression
Excerpt from the Press Release:
BURLINGAME, Calif.–(BUSINESS WIRE)–Magnus Medical, Inc., a pioneering therapeutic neuromodulation company transforming the treatment of neuropsychiatric disorders, today announced promising new clinical data on SAINT® therapy at the 2024 NYC Neuromodulation Conference, Aug 1-3. The research will be presented in two posters demonstrating the long-lasting benefits of SAINT treatment and its potential for personalized continuation therapy in people with treatment-resistant depression (TRD).
“We’re excited to share these new findings at this year’s NYC Neuromodulation Conference, which further validate the transformative potential of the SAINT therapy in providing durable relief for people with debilitating intractable depression and offering a pathway for personalized continuation treatment to maintain remission,” said Brandon Bentzley, M.D., Ph.D., co-founder and CSO, Magnus Medical. “The potential life-saving impact is truly inspiring.”
“Furthermore, building on the strength of this compelling research, we are rapidly expanding access to the SAINT neuromodulation system, delivering it to hospitals and private clinics across the country,” continued Dr. Bentzley.
Research Highlights:
- Durability of clinical benefit with Stanford Neuromodulation Therapy (SNT, commercially known as SAINT) in treatment-resistant depression: assessment of sustained remission and response following index treatment
This study, conducted by researchers at Stanford University, provides the first longer-term data on the durability of SAINT’s antidepressant effect in patients with TRD. The results indicate that a single five-day course of treatment offers substantial and durable clinical benefits, with patients remaining in remission for an average of 11 weeks and in a state of response for an average of 15 weeks.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?